Schonfeld Strategic Advisors LLC Decreases Stake in enGene Holdings Inc. (NASDAQ:ENGN)

Schonfeld Strategic Advisors LLC reduced its stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) by 56.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 132,260 shares of the company’s stock after selling 173,774 shares during the period. Schonfeld Strategic Advisors LLC owned 0.30% of enGene worth $880,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. acquired a new stake in enGene during the fourth quarter worth $69,000. Franklin Resources Inc. raised its holdings in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Finally, Blue Owl Capital Holdings LP raised its holdings in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock valued at $21,014,000 after purchasing an additional 101,006 shares in the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ENGN has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Tuesday, March 11th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. Piper Sandler began coverage on enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 target price on the stock. Morgan Stanley cut their price target on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, UBS Group cut enGene from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, enGene currently has an average rating of “Buy” and a consensus price target of $23.29.

enGene Price Performance

enGene stock opened at $3.36 on Friday. enGene Holdings Inc. has a 12-month low of $3.27 and a 12-month high of $14.67. The firm’s 50-day moving average is $4.45 and its two-hundred day moving average is $6.34. The stock has a market capitalization of $171.28 million, a P/E ratio of -5.79 and a beta of -0.36. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.